Ludovic Croxford



  • Ludovic Croxford
    Ludovic Croxford

    2000 - PhD Medical Immunology, University College London

    1994 - BSc Biochemistry and Toxicology, University of Surrey


    Academic Background

    Dr Croxford is a multi-disciplinary immunologist with research experience in a wide range of fields, especially neuroimmunology, autoimmunity, and oncology. His PhD research demonstrated the potential use of cytokine gene therapy for the treatment of animal models of autoimmune disease, and his post-doctoral research focused on the mechanisms of viral molecular mimicry to induce autoimmunity. Dr Croxford next studied the role of a novel NKT cell in a multiple sclerosis model at the National Institute of Neurology, National Center of Neurology and Psychiatry, Tokyo, Japan. Following this, he studied the mechanisms of immune-mediated tumor suppression for leukemia.

    Publishing History

    Dr Croxford has published over 40 peer-reviewed papers, reviews, and book chapters in journals including Nature, Nature Immunology and Nature Medicine.

    Editing and Reviewing Experience

    Dr Croxford began editing papers for his colleagues in Japan and has been editing scientific papers since 2007, with over 2000 edited manuscripts to date. He was an ad hoc reviewer for numerous peer-reviewed Life Science journals including Drugs Journal, PNAS, European Journal of Immunology, Journal of Neurochemistry, Journal of Leukocyte Biology, Clinical and Experimental Immunology, Biochemical Pharmacology, Infections and Immunity Triage – Medical Research Council, Current Drug Targets – CNS and Neurological Disorder, Biodrugs Journal, and Immunology. Dr Croxford joined Edanz as an editor in 2011.

    Writing Experience

    Dr Croxford has written a number of book chapters for Autoimmunity: Methods and Protocols in Methods in Molecular Medicine, Stem Cell Transplantation for Autoimmune Disease, and Recent Research Developments in Immunology Volume 1, Part 1. He has also written abstracts and papers for biotech and pharmaceutical companies.